These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
786 related items for PubMed ID: 9267721
1. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy. Cantarovich M, Latter DA, Loertscher R. Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721 [Abstract] [Full Text] [Related]
2. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation? Wagner FM, Reichenspurner H, Uberfuhr P, Kur F, Kaulbach HG, Meiser BM, Ziegler U, Reichart B. J Heart Lung Transplant; 1994 Aug; 13(3):438-42; discussion 442-3. PubMed ID: 8061020 [Abstract] [Full Text] [Related]
3. Induction therapy with cyclosporine without cytolytic agents results in a low incidence of acute rejection without significant renal impairment in heart transplant patients. Jazzar A, Fagiuoli S, Sisson S, Zuhdi N, Cooper DK. Clin Transplant; 1995 Aug; 9(4):334-9. PubMed ID: 7579743 [Abstract] [Full Text] [Related]
4. Treatment of renal allograft acute rejection with methylprednisolone: effect of fixed dose versus dose per body mass index. Douzdjian V, Rice JC, Gugliuzza KK, Fisch JC, Carson RW. Clin Transplant; 1996 Jun; 10(3):310-5. PubMed ID: 8826672 [Abstract] [Full Text] [Related]
5. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Rosen HR, Shackleton CR, Higa L, Gralnek IM, Farmer DA, McDiarmid SV, Holt C, Lewin KJ, Busuttil RW, Martin P. Am J Gastroenterol; 1997 Sep; 92(9):1453-7. PubMed ID: 9317061 [Abstract] [Full Text] [Related]
7. OKT3 induction and steroid-free maintenance immunosuppression for treatment of high-risk heart transplant recipients. Prieto M, Lake KD, Pritzker MR, Jorgensen CR, Arom KV, Love KR, Emery RW. J Heart Lung Transplant; 1991 Jun; 10(6):901-11. PubMed ID: 1661608 [Abstract] [Full Text] [Related]
8. Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. McVicar JP, Kowdley KV, Emond MJ, Barr D, Marsh CL, Carithers RL, Perkins JD. Clin Transplant; 1997 Aug; 11(4):328-33. PubMed ID: 9267724 [Abstract] [Full Text] [Related]
9. [Kidney-pancreas transplantation. Clinical results in 23 consecutive patients]. Maestri M, Krieger N, Kuo P, Dafoe DC, Alfrey EJ. Minerva Chir; 1998 Mar; 53(3):121-8. PubMed ID: 9617106 [Abstract] [Full Text] [Related]
10. HLA-DR incompatibility predicts heart transplant rejection independent of immunosuppressive prophylaxis. Costanzo-Nordin MR, Fisher SG, O'Sullivan EJ, Johnson M, Heroux A, Kao W, Mullen GM, Radvany R, Robinson J. J Heart Lung Transplant; 1993 Mar; 12(5):779-89. PubMed ID: 8241215 [Abstract] [Full Text] [Related]
11. Efficacy of OKT3 therapy for acute rejection in isolated lung transplantation. Shennib H, Massard G, Reynaud M, Noirclerc M. J Heart Lung Transplant; 1994 Mar; 13(3):514-9. PubMed ID: 8061029 [Abstract] [Full Text] [Related]
12. Predicting factors of long-term results of OKT3 therapy for steroid resistant acute rejection following cadaveric renal transplantation. Rostaing L, Chabannier MH, Modesto A, Rouzaud A, Cisterne JM, Tkaczuk J, Durand D. Am J Nephrol; 1999 Mar; 19(6):634-40. PubMed ID: 10592356 [Abstract] [Full Text] [Related]
13. OKT3 escalating dose regimens provide effective therapy for renal allograft rejection. Woodle ES, Bruce DS, Josephson M, Cronin D, Newell KA, Millis JM, Piper JB, O'Laughlin R, Thistlethwaite JR. Clin Transplant; 1996 Aug; 10(4):389-95. PubMed ID: 8884115 [Abstract] [Full Text] [Related]
14. Methotrexate or total lymphoid radiation for treatment of persistent or recurrent allograft cellular rejection: a comparative study. Ross HJ, Gullestad L, Pak J, Slauson S, Valantine HA, Hunt SA. J Heart Lung Transplant; 1997 Feb; 16(2):179-89. PubMed ID: 9059929 [Abstract] [Full Text] [Related]
15. Left ventricular dysfunction after heart transplantation: incidence and role of enhanced immunosuppression. McNamara D, Di Salvo T, Mathier M, Keck S, Semigran M, Dec GW. J Heart Lung Transplant; 1996 May; 15(5):506-15. PubMed ID: 8771506 [Abstract] [Full Text] [Related]
16. A randomized prospective trial of prophylactic immunosuppression with ATG-fresenius versus OKT3 after renal transplantation. Bock HA, Gallati H, Zürcher RM, Bachofen M, Mihatsch MJ, Landmann J, Thiel G. Transplantation; 1995 Mar 27; 59(6):830-40. PubMed ID: 7701577 [Abstract] [Full Text] [Related]
17. A randomized prospective study comparing low-dose OKT3 to low-dose ATG for the treatment of acute steroid-resistant rejection episodes in kidney transplant recipients. Mariat C, Alamartine E, Diab N, de Filippis JP, Laurent B, Berthoux F. Transpl Int; 1998 Mar 27; 11(3):231-6. PubMed ID: 9638854 [Abstract] [Full Text] [Related]
18. Methotrexate for rejection prophylaxis after heart transplantation. Taylor DO, Olsen SL, Ensley RD, Renlund DG. J Heart Lung Transplant; 1995 Mar 27; 14(5):950-4. PubMed ID: 8800732 [Abstract] [Full Text] [Related]
19. Management of acute rejection of kidney allograft. Yu LX, Jia YB, Zhang Y. Di Yi Jun Yi Da Xue Xue Bao; 2002 Aug 27; 22(8):752-4. PubMed ID: 12376272 [Abstract] [Full Text] [Related]